Collins, Robert H.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia

Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., et al. (2022) · Cancer Cell

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 403

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration

Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., et al. (2018) · Nature

Immune Cell Function and InteractionCancer Immunotherapy and Biomarkers

Cited by 305

Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia

Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports

Acute Myeloid Leukemia ResearchCytokine Signaling Pathways and Interactions

Cited by 270

Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia

Khoury, H. J., Collins, R. H., Blum, W., Stiff, P. S., Elias, L., Lebkowski, J. S., Reddy, A., Nishimoto, K. P., Sen, D., Wirth, E. D., et al. (2017) · Cancer

Immunotherapy and Immune ResponsesAcute Myeloid Leukemia Research

Cited by 102